Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Relmada Therapeutics (RLMD) Enterprise Value (2016 - 2026)

Relmada Therapeutics has reported Enterprise Value over the past 3 years, most recently at -$2626.0 for Q1 2014.

  • Quarterly Enterprise Value rose 65.01% to -$2626.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was -$2626.0 through Feb 2014, up 65.01% year-over-year, with the annual reading at -$15290.0 for FY2013, 70.86% down from the prior year.
  • Enterprise Value was -$2626.0 for Q1 2014 at Relmada Therapeutics, up from -$6166.0 in the prior quarter.
  • Over five years, Enterprise Value peaked at -$2626.0 in Q1 2014 and troughed at -$15290.0 in Q3 2013.
  • The 3-year median for Enterprise Value is -$8226.5 (2012), against an average of -$8496.8.
  • Year-over-year, Enterprise Value plummeted 70.86% in 2013 and then soared 65.01% in 2014.
  • A 3-year view of Enterprise Value shows it stood at -$10446.0 in 2012, then skyrocketed by 40.97% to -$6166.0 in 2013, then skyrocketed by 57.41% to -$2626.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Enterprise Value are -$2626.0 (Q1 2014), -$6166.0 (Q4 2013), and -$15290.0 (Q3 2013).